Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer

被引:0
|
作者
Mantz, CA
Vokes, EE
Stenson, K
Kies, MS
Mittal, B
Witt, ME
List, MA
Weichselbaum, RR
Haraf, DJ
机构
[1] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
[4] Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA
[5] Northwestern Univ, Dept Radiat Oncol, Chicago, IL 60611 USA
[6] Northwestern Univ, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
来源
CANCER JOURNAL | 2001年 / 7卷 / 02期
关键词
oropharyngeal cancer; chemoradiotherapy; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Locoregionally advanced oropharyngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been pear. Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials. Herein, we report overall survival, progression-free survival, and patterns of failure in locoregionally advanced oropharyngeal cancer treated with induction chemotherapy with or without conservative surgery followed by concomitant chemoradiation. MATERIALS AND METHODS Three cycles of induction chemotherapy consisting of cisplatin, 5-fluorouracil, leucovorin, and interferon alpha -2b (PFL-IFN) were followed by conservative, organ-sparing surgery for residual disease. All patients then proceeded to concomitant chemoradiation consisting of seven or eight cycles of 5-fluorouracil, hydroxyurea, and a total radiotherapy dose of roughly 7000 cGy. RESULTS Sixty-one patients with predominantly stage IV disease were treated. Clinical complete response was observed in 65% of patients after induction therapy. The median follow-up was 68.0 months for survivors and 39.0 months for all patients. At 5 years, overall survival is 51%, progression-free survival is 64%, locoregional control is 70%, and distant control is 89%. Locoregional recurrence accounted far 80% of all initial failures. Only five radical surgeries (none were total glossectomy) were performed for initial disease control. Treatment-related toxicity accounted for four deaths. CONCLUSION PR-IFN given with 5-fluorouracil, hydroxyurea, and radiotherapy produces a high rate of cures with organ preservation in a disease group that has traditionally fared poorly. Local and distant disease control and survival rates exceed those observed with more standard treatment approaches involving surgery and radiotherapy. Further investigation into chemoradiotherapy as a curative modality for this disease is warranted.
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [31] Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Ready, Neal E.
    Rathore, Ritesh
    Johnson, Tirrell T.
    Nadeem, Ahmed
    Chougule, Prakash
    Ruhl, Charles
    Radie-Keane, Kathy
    Theall, Kathy
    Wanebo, Harold J.
    Marcello, Jennifer
    Kennedy, Teresa
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 6 - 12
  • [32] Induction Chemotherapy with Nedaplatin with 5-FU Followed by Intensity-modulated Radiotherapy Concurrent with Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
    Zheng, Jijun
    Wang, Ge
    Yang, Gary Y.
    Wang, Daoyuan
    Luo, Xizhong
    Chen, Chuan
    Zhang, Zhimin
    Li, Qiong
    Xu, Wen
    Li, Zengpeng
    Wang, Dong
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (05) : 425 - 431
  • [33] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Nakachi, Kohei
    Furuse, Junji
    Kinoshita, Taira
    Kawashima, Mitsuhiko
    Ishii, Hiroshi
    Ikeda, Masafumi
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 527 - 534
  • [34] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Junji Furuse
    Taira Kinoshita
    Mitsuhiko Kawashima
    Hiroshi Ishii
    Masafumi Ikeda
    Shuichi Mitsunaga
    Satoshi Shimizu
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 527 - 534
  • [35] Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer
    Byrne, MJ
    Phillips, M
    Powell, A
    Cameron, F
    Joseph, D
    Spry, N
    Dewar, J
    Van Hazel, G
    Buck, M
    Lund, H
    De Melker, Y
    Newman, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (06) : 336 - 342
  • [36] A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
    Lerouge, Delphine
    Riviere, Alain
    Dansin, Eric
    Chouaid, Christos
    Dujon, Cecile
    Schott, Roland
    Lavole, Armelle
    Le Pennec, Vincent
    Fabre, Elizabeth
    Crequit, Jacky
    Martin, Francis
    Dehette, Stephanie
    Fournel, Pierre
    Precheur-Agulhon, Benedicte
    Lartigau, Eric
    Zalcman, Gerard
    BMC CANCER, 2014, 14
  • [37] A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
    Delphine Lerouge
    Alain Rivière
    Eric Dansin
    Christos Chouaid
    Cécile Dujon
    Roland Schott
    Armelle Lavole
    Vincent Le Pennec
    Elizabeth Fabre
    Jacky Crequit
    Francis Martin
    Stéphanie Dehette
    Pierre Fournel
    Bénédicte Precheur-Agulhon
    Eric Lartigau
    Gérard Zalcman
    BMC Cancer, 14
  • [38] neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: real world data from the national institute of oncology, Morocco
    El Gueddari, Rania
    Sara, Abdou
    Hassnaoui, Imane
    Taouchikht, Mona
    Fares, Houda
    Ngbwa, Edith Tatiana
    Nouni, Karima
    Lachgar, Amine
    ElKacemi, Hanane
    Kebdani, Tayeb
    Hassouni, Khalid
    RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S166 - S167
  • [39] Induction Chemotherapy Before Chemoradiotherapy in Locally Advanced Head and Neck Cancer: The Future?
    Paccagnella, Adriano
    Mastromauro, Cataldo
    D'Amanzo, Paola
    Ghi, Maria Grazia
    ONCOLOGIST, 2010, 15 : 8 - 12
  • [40] Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck
    Fountzilas, George
    Bamias, Aristotelis
    Kalogera-Fountzila, Anna
    Karayannopoulou, Georgia
    Bobos, Mattheos
    Athanassiou, Eleni
    Kalogeras, Konstantine T.
    Tolis, Christos
    Tsekeris, Periklis
    Papakostas, Pavlos
    Vamvouka, Chrysanthi
    Zaramboukas, Thomas
    Kosmidis, Paris
    Zamboglou, Nikolaos
    Misailidou, Despina
    ANTICANCER RESEARCH, 2009, 29 (02) : 529 - 538